Incidence, Mortality, and Predictive Factors of Hepatocellular Carcinoma in Primary Biliary Cirrhosis

Table 1

Clinicopathological characteristics of the study population.

Parameters	Male	Female	Overall
Number of patients	24	155	179
Age of diagnosis of primary biliary cirrhosis (years)*	55.5 (22–75)	57 (24–85)	57 (22–85)
Duration of follow-up (months)^*†	96.5 (27–218)	97 (12–281)	97 (12–281)
Number of patients with Scheuer's stage (I/II/III/IV)	13/5/2/4	88/37/17/13	101/42/19/17
Brinkman index*	400 (0–1575)	0 (0–940)	0 (0–1575)
Number of patients with a history of blood transfusion	3	20	23
Number of patients with a history of drinking	4	7	11
Number of symptomatic patients	4	49	53
Pruritus	1	36	37
Jaundice	2	7	9
Ascites	0	3	3
Varices	2	15	17
Biochemical data
AST (IU/L)*	59.5 (26–140)	46.5 (16–258)	49 (16–258)
ALT (IU/L)*	72 (17–233)	41 (10–329)	46 (10–329)
ALP (lU/L)*	652 (94–2113)	501.5 (112–2985)	535.5 (94–2985)
γ-GTP (IU/L)*	350.5 (75–1349)	164 (13–1004)	173.5 (13–1349)
Alb (g/dL)*	4.2 (2.4–5.1)	4.2 (1.9–5.0)	4.2 (1.9–5.1)
T-Bil (mg/dL)*	0.8 (0.3–3.9)	0.7 (0.1–6.3)	0.7 (0.1–6.3)
IgG (mg/dL)*	1660 (1194–3092)	1676 (778–4532)	1660 (778–4532)
IgM (mg/dL)*	482 (72–1465)	346 (48–1660)	352.5 (48–1660)
Plt (×10^4/𝜇L)*	24.4 (8.7–58.1)	20.7 (5.3–48.6)	20.9 (5.3–58.1)
PT (%)*	105.0 (78.0–126.5)	100.0 (44.0–139.0)	100.0 (44.0–139.0)
Number of patients with medications (UDCA/BF/UDCA + BF/none)	17/0/7/0	127/1/22/5	144/1/29/5
Number of deaths during follow-up	4	27	31

*Data expressed as median (range); ^†Data include first year of follow-up.; Alb: albumin; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BF: bezafibrate; 𝛾-GTP: 𝛾-glutamyltranspeptidase; Plt: platelet; PT: prothrombin time; T-Bil: total bilirubin; UDCA: ursodeoxycholic acid.